Cetera Investment Advisers Cuts Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cetera Investment Advisers lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,105 shares of the company’s stock after selling 899 shares during the period. Cetera Investment Advisers’ holdings in Teva Pharmaceutical Industries were worth $1,170,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Oarsman Capital Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $44,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. IFP Advisors Inc boosted its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock worth $96,000 after acquiring an additional 949 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.94 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $19.21 billion, a price-to-earnings ratio of -11.68, a PEG ratio of 1.44 and a beta of 0.62. The company’s 50-day moving average is $15.38 and its two-hundred day moving average is $17.37. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same period in the prior year, the business posted $0.48 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, May 8th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $24.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.